For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge.

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...

GA triggers a rapid and marked decrease in the kinase activity of cyclin E/cyclin-dependent kinase (CDK2) complex coupled with a decline in CDK2 associated with cyclin E, accompanied by the ...

Each of our trillions of cells bustles with activity in a carefully choreographed quest to keep us healthy. At their core, quality control mechanisms ensure that the right proteins are in the right ...

This analysis segregated cell lines into distinct clusters demonstrating specific dependencies on various cyclin and CDK genes, revealing tumor types that are exceptionally dependent on CDK2 and more ...

Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic ...

Although eight systems were provided in this dataset, we only selected cyclin-dependent kinase 2 (CDK2), Tyrosine kinase 2 (TYK2), p38 ... including microsomal prostaglandin E synthases (mPGES), ...

CDK: cyclin-dependent kinase; IC 50: half maximal inhibitory concentration; Phospho-RNAPolyII: phosphorylated RNA polymerase II. *From the corresponding structures in Figure 6.